Last reviewed · How we verify
Reduce need for replacement therapy in hemophilia patients during tooth extraction
Approved treatments
- Cyklokapron · Pfizer Inc.
Tranexamic acid occupies lysine receptor binding sites on plasmin, preventing fibrin dissolution.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Reduce need for replacement therapy in hemophilia patients during tooth extraction patent landscape — cliff calendar, originator estates, attackable patents
- Reduce need for replacement therapy in hemophilia patients during tooth extraction treatment landscape brief
- Reduce need for replacement therapy in hemophilia patients during tooth extraction treatment updates RSS
Frequently asked questions about Reduce need for replacement therapy in hemophilia patients during tooth extraction
What drugs treat Reduce need for replacement therapy in hemophilia patients during tooth extraction?
Tracked treatments include Cyklokapron.
What is the treatment for Reduce need for replacement therapy in hemophilia patients during tooth extraction?
Standard treatment for Reduce need for replacement therapy in hemophilia patients during tooth extraction includes Cyklokapron. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Reduce need for replacement therapy in hemophilia patients during tooth extraction patent cliff · Reduce need for replacement therapy in hemophilia patients during tooth extraction CI report
- Treatment: Cyklokapron · Pfizer Inc.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing